A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.

PHASE2UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 20, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

March 31, 2021

Conditions
Acute Ischemic Stroke
Interventions
DRUG

r-PA

"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."

DRUG

r-PA

"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."

DRUG

Alteplase for Injection

"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."

Trial Locations (1)

100055

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

lead

Angde Biotech Pharmaceutical Co., Ltd.

INDUSTRY

NCT04028518 - A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke. | Biotech Hunter | Biotech Hunter